Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 342 | 110 | 217 |
| Samples | 313 | 102 | 205 |
| Peptides | 236 | 66 | 169 |
Function
ADRA2A · Adrenoceptor alpha 2A
Alpha-2-adrenergic receptors are members of the G protein-coupled receptor superfamily. The alpha-2-adrenergic receptors are a type of adrenergic receptors (for adrenaline or epinephrine), which inhibit adenylate cyclase. These receptors include 3 highly homologous subtypes: alpha2A, alpha2B, and alpha2C. They are involved in regulating the release of neurotransmitter molecules from sympathetic nerves and from adrenergic neurons in the central nervous system. The sympathetic nervous system regulates cardiovascular function by activating adrenergic receptors in the heart, blood vessels and kidney. Studies in mouse revealed that both the alpha2A and alpha2C receptor subtypes were required for presynaptic transmitter release from the sympathetic nervous system in the heart and from central noradrenergic neurons. The alpha-2-adrenergic receptors are also involved in catecholamine signaling by extracellular regulated protein kinase 1 and 2 (ERK1/2) pathways. A clear association between the alpha-2-adrenergic receptor and disease has not been yet established. [provided by RefSeq, Sep 2019].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000280155 | P08913 | 342 | 236 |
Gene Properties
Recurrent Mutations
All 236 amino-acid changes on canonical ENST00000280155 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ADRA2A · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ADRA2A – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 8/40 20% | 0/0 0% |
| Endometrial Carcinoma | 7/42 17% | 24/612 4% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 14/304 5% | 13/1390 1% |
| Colorectal Carcinoma | 14/143 10% | 36/3239 1% |
| Gastric Carcinoma | 1/74 1% | 22/1809 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Bladder Carcinoma | 5/58 9% | 5/956 1% |
| Other Solid Cancers | 2/94 2% | 14/1515 1% |
| Biliary Tract Carcinoma | 0/54 0% | 9/950 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Squamous Cell Lung Carcinoma | 4/57 7% | 3/810 0% |
| Melanoma | 3/210 1% | 13/1899 1% |
| Hodgkins Lymphoma | 1/16 6% | 0/122 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 5/752 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 15/2550 1% |
| Ovarian Carcinoma | 4/109 4% | 3/998 0% |
| Plasma Cell Myeloma | 1/44 2% | 1/305 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Head and Neck Carcinoma | 5/85 6% | 3/1574 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Other Sarcomas | 2/69 3% | 1/699 0% |
| Esophageal Carcinoma | 0/23 0% | 3/769 0% |
| B-Cell Non-Hodgkins Lymphoma | 4/88 5% | 6/2534 0% |
| Non-Cancerous | 1/104 1% | 2/830 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 4/1592 0% |
| Pancreatic Carcinoma | 2/89 2% | 3/1611 0% |
| Prostate Carcinoma | 1/13 8% | 5/2105 0% |
| Glioma | 0/52 0% | 6/2127 0% |
Mutation Distribution
Where ADRA2A is mutated · all tissues, split by cell line vs tissue
How many mutations in ADRA2A were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 342 mutations in ADRA2A
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|